Phacoemulsification in Nanophthalmic Eye, a Way to Manage Glaucoma: Case Report.

Autor: Bamefleh D; Glaucoma Division King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia., Schargel K; Glaucoma Division King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia., Semidey VA; Vitreoretinal Division King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia., Altahan FA; College of Medicine King Saud University Medical City, Riyadh, Saudi Arabia., Schargel E; College of Medicine Medical University of Varna, Varna, Bulgaria.
Jazyk: angličtina
Zdroj: Case reports in ophthalmological medicine [Case Rep Ophthalmol Med] 2024 Jul 01; Vol. 2024, pp. 2633679. Date of Electronic Publication: 2024 Jul 01 (Print Publication: 2024).
DOI: 10.1155/2024/2633679
Abstrakt: A rare condition called nanophthalmos causes variable degrees of vision impairment. One may present with nanophthalmos as a hereditary or sporadic condition. There have been documented cases of nanophthalmos treated with bilateral cataract extraction and intraocular lens (IOL) implantation for intractable secondary glaucoma or chronic angle-closure glaucoma. We describe a case of closed-angle glaucoma in a nanophthalmic eye with increased intraocular pressure (IOP) on full medical treatment, along with concurrent drug side effects. As a first surgical procedure, we recommend phacoemulsification of the clear lens + IOL. The challenge in treating nanophthalmic eyes lies in managing the possibility of developing glaucoma in an eye where anatomical conditions make surgery extremely risky. This must be balanced against the advantages of lessening exposure contact in the trabecular meshwork and optimizing the anterior chamber for potential future glaucoma surgery, which can improve the prognosis in these cases. Lastly, it is critical to have a thorough conversation with the patient about the aims, risks, and advantages. The patient's understanding and expectations should also be crystal apparent. The primary objective should always be to enhance the circumstances for the most effective glaucoma therapy, not to perform refractive surgery.
Competing Interests: The authors declare no conflicts of interest.
(Copyright © 2024 Dania Bamefleh et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje